Pr Anthony BUISSON
@BuissonPr
Followers
41
Following
70
Media
1
Statuses
20
Joined October 2022
RT @IBDGastroDocSg: Do IBD patients with BMI>30 kg/m² require higher subcutaneous IFX doses?. - post-hoc REMSWITCH analysis suggests not.-….
0
8
0
RT @ShomronH: Encouraging results in post-hoc analysis of Upa in CD perianal fistulas. Yet bewildering how 20yrs later, IFX ACCENT2 trial….
0
6
0
RT @JCC_IBD: The GETAID: 40 years of a family story in IBD. Laharie et al. @BouhnikYoram @JeanFredericCo1 @MatFume @PeyrinBiroulet https:/….
academic.oup.com
Abstract. The Groupe d’Etude sur les Affections Inflammatoires Digestives (GETAID) was founded in Paris in 1983 by Professor Robert Modigliani and colleagu
0
2
0
DEVISE-CD project in @AGA_CGH .A new MRI score (C-score) dedicated to define and assess transmural healing and response in patients with CD. C-score is now a validated, reliable and easy-to-use tool to assess therapeutic efficacy.
0
0
4
RT @Bealoquebea: PREDICT UC trial optimizing infliximab dose in patients with #ASUC. Initially no differences at day 8 BUT.✅intensified bet….
0
20
0
0
5
0
RT @afaCrohnRCH: 🟠Tension d'approvisionnement de Questran : l'afa se bat ! Le point sur la situation :
afa.asso.fr
Tension d’approvisionnement du Questran : l’afa se bat !
0
3
0
Happy to publish long-term results of the REMSWITCH study in AP&T confirming that switching from IV to SC infliximab is safe and well-accepted for IBD patients treated with intensified IV regimen and providing practical algorithm to help IBD physicians to safely manage the switch.
@APandT - "Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study" - #GItwitter #IBD #infliximab
4
11
19
RT @JeanFredericCo1: Celebrating 25 years of Adhesive Invasive E. coli.Starting with tribute to our beloved Arlette Darfeuille-Michaud http….
0
6
0
RT @MatFume: Chers amis gastro, nous avons besoin de vous !.Le GETAID lance ICARE II .▶️évaluer en vie réelle la tolérance des nouveaux tra….
0
5
0
RT @JeanFredericCo1: - Took years to recruit bionaive patients ! .- Rationale combination needed to be transformative .- Bayesian analysis….
pubmed.ncbi.nlm.nih.gov
gov number: NCT02764762.
0
46
0
RT @afaCrohnRCH: Les MICI, maladies environnementales ? Le Pr Anthony Buisson nous répond sur l'afa web tv. 👉
0
10
0
RT @afaCrohnRCH: L'afa est à #Chicago pour rencontrer des experts #MICI Français et internationaux à l'occasion de l'exceptionnel Congrès #….
0
6
0
Happy to share with you the results of our real-world comparison between tofacitinib and vedolizumab after anti-TNF failure in UC published in @APandT.
0
0
4
RT @ShomronH: Clever ACCEPT2 study. 1850pts survey by @BuissonPr @MatFume. Shows pts preference for oral Tx is not automatic but depends o….
0
8
0